©The Author(s) 2022.
World J Gastrointest Surg. Feb 27, 2022; 14(2): 161-173
Published online Feb 27, 2022. doi: 10.4240/wjgs.v14.i2.161
Published online Feb 27, 2022. doi: 10.4240/wjgs.v14.i2.161
Table 2 Neoadjuvant therapy and response before and after propensity score matching
| Variable | All patients | P value | Matched patients | P value | ||
| LTG (n = 78) | OTG (n = 107) | LTG (n = 69) | OTG (n = 69) | |||
| Type n (%) | 0.345 | 0.784 | ||||
| NAC | 69 (88.5) | 99 (92.5) | 61 (88.4) | 62 (89.9) | ||
| NCRT | 9 (11.5) | 8 (7.5) | 8 (11.6) | 7 (10.1) | ||
| NAC regimens n (%) | 0.491 | 0.659 | ||||
| Platinum-based doublets | 41 (59.4) | 64 (64.6) | 36 (59.0) | 39 (62.9) | ||
| Epirubicin/taxane-based triplets | 28 (40.6) | 35 (35.4) | 25 (41.0) | 23 (37.1) | ||
| Cycles | 3.3 ± 1.3 | 3.8 ± 1.8 | 0.086 | 3.3 ± 1.3 | 3.6 ± 1.6 | 0.300 |
| Clinical response n (%) | 0.939 | 0.859 | ||||
| PR | 50 (64.1) | 68 (63.6) | 44 (63.8) | 45 (65.2) | ||
| SD | 28 (35.9) | 39 (36.4) | 25 (36.2) | 24 (34.8) | ||
| Mandard TRG score n (%) | 0.316 | 0.654 | ||||
| 1 | 26 (33.3) | 52 (48.6) | 22 (31.9) | 29 (42.0) | ||
| 2 | 4 (5.1) | 4 (3.7) | 4 (5.8) | 2 (2.9) | ||
| 3 | 30 (38.5) | 34 (31.8) | 26 (37.7) | 25 (36.2) | ||
| 4 | 5 (6.4) | 5 (4.7) | 5 (7.2) | 5 (7.2) | ||
| 5 | 13 (16.7) | 12 (11.2) | 12 (17.4) | 8 (11.6) | ||
- Citation: Hu HT, Ma FH, Xiong JP, Li Y, Jin P, Liu H, Ma S, Kang WZ, Tian YT. Laparoscopic vs open total gastrectomy for advanced gastric cancer following neoadjuvant therapy: A propensity score matching analysis. World J Gastrointest Surg 2022; 14(2): 161-173
- URL: https://www.wjgnet.com/1948-9366/full/v14/i2/161.htm
- DOI: https://dx.doi.org/10.4240/wjgs.v14.i2.161